Log in

NASDAQ:SLXP - Salix Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume4.96 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders. The Company offers over 20 marketed products, such as XIFAXAN550 (rifaximin) tablets, XIFAXAN (rifaximin) tablets, APRISO (mesalamine) extended-release capsules, UCERIS (budesonide MMX) extended release tablets, MOVIPREP, GLUMETZA extended release tablets, RELISTOR subcutaneous injection, UCERIS rectal foam, OSMOPREP tablets, SOLESTA, DEFLUX, FULYZAQ (crofelemer) delayed-release tablets, GIAZO (balsalazide disodium) tablets, CYCLOSET (bromocriptine mesylate) tablets, and FENOGLIDE (fenofibrate) tablets, among others. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SLXP
CUSIP79543510
Phone+1-919-8621000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SLXP News and Ratings via Email

Sign-up to receive the latest news and ratings for SLXP and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

Salix Pharmaceuticals (NASDAQ:SLXP) Frequently Asked Questions

What is Salix Pharmaceuticals' stock symbol?

Salix Pharmaceuticals trades on the NASDAQ under the ticker symbol "SLXP."

Has Salix Pharmaceuticals been receiving favorable news coverage?

Headlines about SLXP stock have trended somewhat negative this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Salix Pharmaceuticals earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Salix Pharmaceuticals.

Who are some of Salix Pharmaceuticals' key competitors?

What other stocks do shareholders of Salix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Salix Pharmaceuticals investors own include Baidu (BIDU), Gilead Sciences (GILD), Allergan (AGN), Qihoo 360 Technology (QIHU), Celgene (CELG), Intercept Pharmaceuticals (ICPT), 3D Systems (DDD), Johnson & Johnson (JNJ), Michael Kors (KORS) and Palo Alto Networks (PANW).

What is Salix Pharmaceuticals' official website?

The official website for Salix Pharmaceuticals is http://www.salix.com/.

How can I contact Salix Pharmaceuticals?

Salix Pharmaceuticals' mailing address is 8510 Colonnade Center Dr, RALEIGH, NC 27615-3050, United States. The specialty pharmaceutical company can be reached via phone at +1-919-8621000.


MarketBeat Community Rating for Salix Pharmaceuticals (NASDAQ SLXP)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  693
MarketBeat's community ratings are surveys of what our community members think about Salix Pharmaceuticals and other stocks. Vote "Outperform" if you believe SLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel